Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.58 |
| ▸ | TPMT | P51580 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SELL | P14151 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SELP | P16109 | 1/20 | 0.39 |
| ▸ | FUT4 | P22083 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29172048 | 0.86 | TTR (0.48) | TTRTPMTCA12CA1CA2 | |
| SCHEMBL30848312 | 0.86 | TTR (0.48) | TTRTPMTCA12CA1CA2 | |
| SCHEMBL28198982 | 0.82 | TTR (0.58) | TTRTPMTCA12CA1CA2 | |
| SCHEMBL29171894 | 0.82 | TTR (0.44) | TTRTPMTALDH1A1HPGD | |
| SCHEMBL30848231 | 0.82 | TTR (0.44) | TTRTPMTALDH1A1HPGD | |
| SCHEMBL1856918 | 0.80 | TTR (0.56) | TTRTPMTCA12CA1CA2 | |
| SCHEMBL7122207 | 0.75 | TTR (0.68) | TTRTPMTCA12CA1CA2 | |
| SCHEMBL16077698 | 0.75 | TTR (0.67) | TTRTPMTCA12CA1CA2 | |
| SCHEMBL6642771 | 0.75 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1237714 | 0.74 | TPMT (0.46) | TTRTPMTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676498-B2 | Processes for the preparation of sofosbuvir and intermediates thereof | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2020-06-09 | — | — | US | disclosed |
| US-20190218243-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF SOFOSBUVIR AND INTERMEDIATES THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2019-07-18 | — | — | US | disclosed |
| EP-3303362-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF SOFOSBUVIR AND INTERMEDIATES THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016196735-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF SOFOSBUVIR AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2016-12-08 | — | — | WO | disclosed |
| US-20070027215-A1 | Nuclear receptor ligands and ligand binding domains | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-01 | — | — | US | disclosed |
| EP-0873361-B1 | Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand | UNIV CALIFORNIA (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-0873361-A4 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | UNIV CALIFORNIA (US) | 2002-10-23 | — | — | EP | disclosed |
| US-6236946-B1 | Nuclear receptor ligands and ligand binding domains | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-05-22 | — | — | US | disclosed |
| EP-1034184-A2 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | The Regents of the University of California (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-1999026966-A2 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0873361-A2 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997021993-A2 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676498-B2 | Processes for the preparation of sofosbuvir and intermediates thereof | CYP3A4, EIF2AK2, RTF2 | TTR 2575/4885TPMT 333/4885CA12 4477/4885 |
| US-20070027215-A1 | Nuclear receptor ligands and ligand binding domains | TSHR, NR5A2, THRA | TTR 195/4885TPMT 4628/4885CA12 4461/4885 |
| US-20190218243-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF SOFOSBUVIR AND INTERMEDIATES THEREOF | EIF2AK2, CYP3A4, RTF2 | TTR 2374/4885TPMT 367/4885CA12 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.